• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Therapeutic Class Overview: New Avatars of Microbes Super Bugs a Growing Threat Worldwide Product Image Special Offer Sale Banner

Therapeutic Class Overview: New Avatars of Microbes Super Bugs a Growing Threat Worldwide

  • ID: 2763283
  • February 2014
  • Region: Global
  • 12 Pages
  • MP Advisors
Special Offer Banner
10%
OFF
Offer ends 13th Nov 2014

Novel approaches to treat infection is growing as the need is urgent! Misuse/overuse of antibiotics accelerated antimicrobial resistance (AMR) and has resulted in the emergence of “super bugs” which are posing life threatening challenges world wide. Many of the advances in medical treatment like cancer therapy; organ transplants etc. would go waste if the ability to fight infections during the treatment were not available. If that fails, the gains made in life-improving modern medical advantages will be lost creating a situation of - “one step forward two step back”. Novel approaches are immediately required to combat these “super infections” warranting need for new classes of antibiotics and other preventive/therapeutic approaches.

Discussed in this report:

- The evolution and global dissemination of AMR

- Unmet need in the critical setting esp. Gram Negative infections and CRE.

- Pipeline of novel targets being used to develop new drugs to treat infections and resistance.

- Pipeline of select drugs in mid and late clinical stage of development

- Alarming Facts about AMR

- Steps being taken by the regulatory authorities WW to address the issue and encourage novel therapeutics in this therapy area.

- Developing Countries- /ROW -- Trends in pathogens and resistance

- Role of diagnostics and preventive approach.

Introduction- Evolution and global dissemination of Anti Micorbial Resistance (AMR)

- How has the Problem Manifested to Such an Alarming Level?
- Microbial Evolution has Outpaced Innovation!o

Hitch Hiking and Globe Trotting by “Bad Bugs”-

Unmet need in the critical setting:

- Running Out of Drugs to Treat Serious Gram-Negative Infections
- Carbapenem-resistant Enterobacteriaceae (CREs)
- Evolution of CRE -
- Spreading the Bug

Need of the Hour- New Targets= New Antibiotic Class

- Pipeline of novel targets being used to develop new drugs to treat infections and
resistance.

- Pipeline of select drugs in mid and late clinical stage of development

Alarming Facts about AMR - CDC Alerts

Action by Regulatory Bodies –to Accelerate Drug development and Threat Awareness

US

- The GAIN Act
- Breakthrough Therapies Designation

Europe

- Draft guidance “Expedited Programs for Serious Conditions––Drugs and Biologics”
- Strategic Research Agenda

Developing Countries- /ROW -- Trends in pathogens and resistance

Role of diagnostics and preventive approach

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos